-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TPI-287
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TPI-287 Drug Details ARC-100 (TPI 287) is under development for the treatment of Alzheimer's...
-
Product Insights
Spinal Surgery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Spinal surgery includes devices used in the surgical treatment of degenerative disc diseases, intra-vertebral fractures, and scoliosis. The Spinal Surgery pipeline market research report provides comprehensive information about the Spinal Surgery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Sector Analysis
Neuromodulation Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
The Neuromodulation Devices pipeline market research report provides comprehensive information about the Neuromodulation Devices pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Corticobasal Degeneration (CBD-CBGD-Cortical Basal Ganglionic Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics,...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...
-
Product Insights
Medulloblastoma – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Medulloblastoma - Global Clinical Trials Review, H2, 2021" provides an overview of Medulloblastoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Medulloblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
Medulloblastoma Disease – Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Medulloblastoma Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Medulloblastoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Medulloblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Japan Cardiovascular Devices Market Outlook to 2025 – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices and Others
GlobalData’s “Japan Cardiovascular Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Japan Cardiovascular Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices, Cardiac Rhythm Management Devices, Cardiovascular Prosthetic Devices, Cardiovascular Surgery Devices, Clot Management Devices, Electrophysiology Devices, Interventional Cardiology, Peripheral Vascular Devices and Prosthetic Heart Valves. The Japan Cardiovascular Devices Market report provides...
-
Sector Analysis
PharmaFocus: Tauopathies–Global Market Analysis
Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical companies in particular. These are: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease (clinically referred to as bvFTD), and chronic traumatic encephalopathy (CTE). In these indications, symptoms often present as behavioral (e.g. disinhibition,...